PIK3CA and breast cancer: For patients with hormone receptor (HR)-positive, HER2-negative metastatic BC, standard treatment is based on endocrine therapy, although tumors frequently develop resistance, primarily due to the presence of activating mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA; 40% of cases) [38].